Biotech · Private company
Suven Life Sciences Limited
Track this companyFree. Adds Suven Life Sciences Limited to your Dealase workspace and tells you when its record changes.
Clinical trials72 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- Masupirdine 100 mgPhase 3 · AgitationClinicalTrials.gov · fetched Nov 12, 2026
- Masupirdine 50 mgPhase 3 · AgitationClinicalTrials.gov · fetched Nov 12, 2026
- SamelisantPhase 3 · NarcolepsyClinicalTrials.gov · fetched Nov 12, 2026
- DonepezilPhase 2 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- MemantinePhase 2 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- RopanicantPhase 2 · Major Depressive Disorder (MDD)ClinicalTrials.gov · fetched Nov 12, 2026
- RopanicantPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- SUVN-502Phase 2 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SUVN-G3031Phase 2 · NarcolepsyClinicalTrials.gov · fetched Nov 12, 2026
- SUVN-I6107Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)PHASE3 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07540364 · fetched Nov 12, 2026
- Study to Evaluate Efficacy and Safety of Ropanicant in MDD PatientsPHASE2 · COMPLETED · started Jul 15, 2025ClinicalTrials.gov NCT06836063 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy ParticipantsPHASE1 · COMPLETED · started Jan 7, 2025ClinicalTrials.gov NCT06705088 · fetched Nov 12, 2026
- Study Evaluating Safety and Efficacy of Ropanicant in MDD PatientsPHASE2 · COMPLETED · started Feb 5, 2024ClinicalTrials.gov NCT06126497 · fetched Nov 12, 2026
- Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypePHASE3 · ACTIVE_NOT_RECRUITING · started Nov 1, 2022ClinicalTrials.gov NCT05397639 · fetched Nov 12, 2026
- A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without CataplexyPHASE2 · COMPLETED · started Sep 21, 2019ClinicalTrials.gov NCT04072380 · fetched Nov 12, 2026
- SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a StudyPHASE2 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02580305 · fetched Nov 12, 2026